Amgen Inc (AMGN)
$360.90+2.29%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Sixteen growing drugs and strong cash flow; European lung cancer approval adds momentum while debt unwinds.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque ps…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $182.2B
Recent dividends
- 15 May 2026$2.52
- 13 Feb 2026$2.52
- 21 Nov 2025$2.38
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Amgen Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free